Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

NCT07241793 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Advanced Urothelial Carcinoma
Urothelial Carcinoma Recurrent

Interventions

DRUG: Adebrelimab
DRUG: Trastuzumab Rezetecan

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]